)

NRx Pharmaceuticals (NRXP) investor relations material
NRx Pharmaceuticals Noble Capital Markets Emerging Growth Virtual Investor Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Recent developments and strategic focus
Intends to generate revenue starting this year, with growth expected over the next two years, driven by three lead programs.
NRX-100 (IV ketamine) is being advanced for FDA approval for suicidal ideation and depression, with a broad fast-track indication and a potential $2 billion market.
NRX-101, a combination therapy, has breakthrough therapy designation and is the first oral drug shown to reduce suicidality in akathisia.
Building a network of HOPE Therapeutics clinics to integrate neuroplastic therapies for depression, PTSD, autism, and brain injury.
Developing a preservative-free generic ketamine (KETAFREE) for anesthesia and pain control, targeting a $750 million market.
Clinical and scientific advancements
Real-world and clinical trial data show IV ketamine significantly reduces suicidality and depression, with new evidence supporting its use in PTSD.
D-cycloserine, especially at low doses, enhances the effect of transcranial magnetic stimulation (TMS) for depression and suicidality.
Hyperbaric oxygen therapy and digital therapeutics are being integrated as additional neuroplastic interventions.
Combining neuroplastic drugs, TMS, and other therapies is believed to offer a durable path to recovery for suicidal depression and PTSD.
Treatments are cost-effective, with full courses delivered for less than $10,000, significantly lower than other major interventions.
Regulatory and market landscape
FDA granted a fast-track designation and a filing fee waiver for NRX-100; a Commissioner's National Priority Voucher (CNPV) could accelerate approval.
KETAFREE is back on file with the FDA after reformulation to match generic standards.
No FDA-approved drugs currently exist for suicidal ideation; current treatments like ECT have significant drawbacks.
The administration and federal agencies have made veteran suicide and mental health a top priority, with strong support for innovative treatments.
If granted, a CNPV would significantly speed up the regulatory timeline for NRX-100; otherwise, a six-month NDA review is expected.
Next NRx Pharmaceuticals earnings date

Next NRx Pharmaceuticals earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage